PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients

A real-world setting study of familial hypercholesterolemia (FH) patients who received Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in a specialized referral center in Mexico City. Ten patients between the ages of 18 and 70 years, with a diagnosis of FH according to Dutch Lipid C...

Descripción completa

Detalles Bibliográficos
Autores principales: Ceballos-Macías, José Juan, Lara-Sánchez, Carolina, Flores-Real, Jorge, Aguilar-Salinas, Carlos Alberto, Ortega-Gutiérrez, Guillermo, Vargas-Sánchez, Joel, Madriz-Prado, Ramón, Derosa, Giuseppe, Rodríguez-Benítez, Hazel, Baltazar-Romero, Ricardo, Lopez-Mezquita, Dante José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747364/
https://www.ncbi.nlm.nih.gov/pubmed/33367195
http://dx.doi.org/10.1210/jendso/bvaa180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747364/
https://www.ncbi.nlm.nih.gov/pubmed/33367195
http://dx.doi.org/10.1210/jendso/bvaa180

Ejemplares similares